Skip to main content
. 2020 Nov 25;14(1):13. doi: 10.3892/mco.2020.2175

Figure 1.

Figure 1

(A and B) PFS and (C and D) OS of patients with soft tissue sarcoma treated with eribulin by histological subtype. PFS, progression-free survival; OS, overall survival; CI, confidence interval.